Appointment of Chief Financial Officer
Appointment of Chief Financial Officer
York, U.K. 26 January 2021: Abingdon Health plc (AIM: ABDX) ("Abingdon Health" or "the Company"), a leading international developer and manufacturer of high quality and effective rapid tests, today announces the appointment of Melanie Ross to the Board and as Chief Financial Officer with immediate effect.
Melanie is a highly experienced executive with a strong track record of process and business improvement, and has broad experience in managing rapidly growing businesses, fund raisings, acquisitions, and corporate governance. Most recently she was Group Finance Director at GVO-B1 Ltd, and prior to that served as Chief Financial Officer and Chief Operating Officer at AIM-listed Surgical Innovations Group Plc where she was instrumental in leading the Company to profitability. Melanie holds a BA (Hons) in Accounting and Finance from the Nottingham Trent University.
Scott Page, Finance Director, will report directly to Melanie Ross. Scott will be stepping down from the Board of Abingdon Health and has been appointed as company secretary.
Dr Chris Hand, Chairman of Abingdon Health said: "I am delighted to welcome Melanie Ross to the Board as Chief Financial Officer following our successful IPO on AIM. Melanie is a highly talented, well-respected and experienced leader and her financial acumen, and track record of helping to grow businesses will be invaluable as we accelerate growth to meet the market demand for high quality and effective rapid tests. I would also like to thank Scott Page on behalf of the Abingdon Health Board for his dedication and hard work during an extensive period of growth for the company and we look forward to continue working with him in the future."
Melanie Ross, Chief Financial Officer of Abingdon Health commented: "Having seen the way the company has responded to the Covid-19 pandemic and its growth in 2020, I'm highly excited to be joining Abingdon Health at this time. To be part of the development and roll-out the AbC-19TM Rapid Test for antibodies to Covid-19, a powerful diagnostic tool for these times, as well as a portfolio of other Covid-19 and non-Covid-19 lateral flow services in areas such as infectious disease, oncology, and animal health, is something I am relishing. I look forward to working with the Board and management team to realise the vision of Abingdon being a world recognised leader in rapid testing technology."
Additional Disclosures Required under the AIM Rules for Companies
In accordance with Schedule 2(g) of the AIM Rules, Melanie Ross, nee Williams (aged 41) does not hold any current directorships.
Previous directorships and partnerships held in the past five years:
Surgical Innovations Group plc
Surgical Innovations Ltd
Surgical Innovations (UK) Limited
Core Precision Limited
Elemental Healthcare Ltd
Melanie Ross does not currently have an interest in any ordinary shares in the Company.
There is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.
Abingdon Health plc
Chief Executive Officer
Dr Chris Hand
Sole Broker and NOMAD
Tel: +44 (0) 20 7496 3000
Shaun Dobson, Pete Steel and Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)
Tel: +44 (0) 7720 088 468
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York, England.
BrainCool AB (publ): BrainCool omstrukturerar för att öka flexibiliteten och planerar byte till Nasdaq First North under Q2 2022
All hänförlig personal, patent, varumärken och rättigheter samt väsentliga avtal överförs. I samband med omstruktureringen kommer Christian Strand, som är ansvarig för affärsutveckling inom BrainCool, utses till tf VD för CoolPrevent AB. VD kommer att bilda en ledningsgrupp med styrelseledamöterna R...
Framtagning av lågtiter blodgrupp 0 helblod: Presentation av resultat vid SABM 2021 (översättning)
Översättning av PM SEP 24, 2021 17:15 CET:Manufacturing of low titer-blood group O whole blood: Presentation of results at the SABM 2021 Annual Meeting Glycorex Transplantation AB (publ.), noterat på NGM Main Regulated Equity, meddelar att Transfusionenheten vid University of R...
Voluntis announces its results for the first half of 2021
Decline in commercial invoicing to€ 1.5 million and IFRS revenue to€ 1.3 million in H1 2021 Significant increase in deferred revenues to€ 11.6 million at 30 June 2021 Significant reduction in operational expenses as part of the strategic roadmap announced in Marc...
Voluntis annonce ses résultats du 1er semestre 2021
Recul des facturations commerciales à 1,5 million d'euros et du chiffre d'affaires IFRS à 1,3 million d'euros au 1er semestre 2021 ; Progression sensible des produits constatés d'avance à 11,6 millions d'euros au 30 juin 2021; Réductio...